COMMUNIQUÉS West-GlobeNewswire

-
Ambu A/S: Financial Diary
30/09/2019 -
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
30/09/2019 -
ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies
30/09/2019 -
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
30/09/2019 -
NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER
30/09/2019 -
NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL
30/09/2019 -
Aino Health AB (publ): Aino Health signs cooperation agreement with Monetra Oulu Oy
30/09/2019 -
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
30/09/2019 -
OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
30/09/2019 -
SPINEWAY : Spineway réalise une augmentation de capital de 1,3 M€
30/09/2019 -
Change in number of shares and votes in Saniona AB (publ)
30/09/2019 -
Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15
30/09/2019 -
Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15
30/09/2019 -
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
30/09/2019 -
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
30/09/2019 -
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
30/09/2019 -
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
30/09/2019 -
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
30/09/2019 -
Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update
30/09/2019
Pages